{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:07:15Z","timestamp":1793275635062,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cllc.2022.08.013","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T22:03:16Z","timestamp":1661810596000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study"],"prefix":"10.1016","volume":"24","author":[{"suffix":"MD, PhD","given":"Pierre","family":"Mordant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Brosseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Milleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Santelmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Fraboulet-Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Langlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Gossot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal-Alexandre","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ricordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannick","family":"Madelaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gine","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Missy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Blons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.08.013_bib0001","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0002","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jtho.2019.10.019","article-title":"The IASLC lung cancer staging project: analysis of resection margin status and proposals for residual tumor descriptors for non-small cell lung cancer","volume":"15","author":"Edwards","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"10026","key":"10.1016\/j.cllc.2022.08.013_bib0005","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2022.08.013_bib0006","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0007","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/JTO.0b013e318211dcee","volume":"6","author":"Beau-Faller","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2022.08.013_bib0008","doi-asserted-by":"crossref","first-page":"e68945","DOI":"10.1371\/journal.pone.0068945","article-title":"Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience","volume":"8","author":"Blons","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2022.08.013_bib0009","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jmoldx.2013.07.009","article-title":"A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting\u2013IFCT\/ERMETIC2 Project Part 1: comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms","volume":"16","author":"Beau-Faller","year":"2014","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.cllc.2022.08.013_bib0010","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","article-title":"Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials","volume":"23","author":"Bell","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0011","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0012","series-title":"Proc Natl Acad Sci U S A.","first-page":"13306","article-title":"EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004"},{"key":"10.1016\/j.cllc.2022.08.013_bib0013","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1200\/JCO.2005.08.043","article-title":"EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment","volume":"23","author":"Marchetti","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0014","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JTO.0000000000000516","article-title":"Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience","volume":"10","author":"Sholl","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0015","first-page":"30982","article-title":"Clinical impacts of EGFR mutation status: analysis of 5,780 surgically resected lung cancer cases","volume":"S0003-4975","author":"Suda","year":"2020","journal-title":"Ann Thorac Surg"},{"issue":"Suppl 2","key":"10.1016\/j.cllc.2022.08.013_bib0016","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1097\/01.JTO.0000269737.05962.a0","article-title":"Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer","volume":"2","author":"Shepherd","year":"2007","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.cllc.2022.08.013_bib0017","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","article-title":"Erlotinib in lung cancer - molecular and clinical predictors of outcome","volume":"353","author":"Tsao","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cllc.2022.08.013_bib0018","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.2005.07.799","article-title":"Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions","volume":"23","author":"Pao","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cllc.2022.08.013_bib0020","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2013.53.1525","article-title":"Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE","volume":"32","author":"Wislez","year":"2014","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.cllc.2022.08.013_bib0021","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant Erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): A randomized, double-blind, phase III Trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0022","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.18.00131","article-title":"SELECT: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"37","author":"Pennell","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.cllc.2022.08.013_bib0023","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib Versus Vinorelbine plus cisplatin as adjuvant treatment for Stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0024","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2022.08.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8501","article-title":"West Japan oncology group. randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung cancer with EGFR mutation (IMPACT)","author":"Tada","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.08.013_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.6752","article-title":"Why not adore ADAURA?-The trial we need vs the trial we got","author":"West","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:13:34Z","timestamp":1761506014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422001978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1525730422001978"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.08.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}